This document is NOT medical advice. COPD is a serious, progressive respiratory disease. Do NOT stop prescribed inhalers, oxygen therapy, or other medications without physician supervision. Severe COPD exacerbations are life-threatening emergencies requiring immediate conventional medical care. These protocols are adjunctive to — never replacements for — standard COPD management. Not FDA approved. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Table of Contents
Overview and Cross-Disease Connections
Chronic obstructive pulmonary disease (COPD) affects approximately 390 million people worldwide and is the third leading cause of death globally. No FDA-approved therapy regenerates destroyed alveolar tissue or reverses established emphysema.
The protocol introduces the Christos™ PulmoLife-COPD fluid (oral delivery only; 24-hour Solfeggio imprinting, 528 Hz primary window). Note: A separate oil-free nebulized variant is in development and has not yet been released. the PCC-1 Pulmonary Coherence Chamber with 30% FiO2 enrichment, 6-field thoracic PBM, and PEMF; the Pulmonary Resonator Patch (home device); and a comprehensive smoking cessation coherence stack. Thirteen falsifiable predictions are provided including FEV1 stabilization, DLCO improvement as an alveolar regeneration signal, and exacerbation reduction exceeding the BRONCUS benchmark.
The Scale of the Problem and the Case for Reversal
1.1 Clinical Landscape
| Parameter | Value |
|---|---|
| Global prevalence | ~390 million people; third leading cause of death worldwide |
| Annual deaths | 3.2 million (WHO 2023); underdiagnosed in 70-80% of affected individuals |
| Primary causes | Cigarette smoking (80-85%); biomass fuel exposure; occupational dust/chemicals; alpha-1 antitrypsin deficiency (1-2%) |
| GOLD staging | Stage I (FEV1 ≥ 80%); Stage II (50-79%); Stage III (30-49%); Stage IV (< 30% or respiratory failure) |
| 5-year mortality | GOLD Stage III: ~40%; Stage IV: ~70% |
| What standard therapy cannot do | Regenerate destroyed alveoli; reverse emphysema; restore normal lung architecture |
1.2 Evidence for Adult Alveolar Regeneration
| Evidence | Finding | Christos™ Implication |
|---|---|---|
| Pneumonectomy model (Hsia 2004, AJRCCM) | Remaining lung grows new alveoli after pneumonectomy in adult humans and animals | Regenerative capacity exists — it requires a sufficient coherence signal |
| AEC2 stem cells (Barkauskas 2013, J Clin Invest) | Type II AECs are stem cells that regenerate alveoli under Wnt/beta-catenin signaling | Coherence field restoration may activate the Wnt/beta-catenin alveolar regeneration pathway |
| HBOT alveolar repair (Wang 2017) | HBOT increases angiogenesis and alveolar repair in elastase-induced emphysema animal models | HBOT provides oxygen substrate and growth factor modulation needed for progenitor activation |
| Smoking cessation (Scanlon 2000) | FEV1 decline slows significantly after cessation; some functional recovery in mild disease | The lung has recovery capacity — cessation provides partial coherence restoration independently |
1.3 The Exacerbation Spiral — Why Prevention Is the Primary Goal
Each acute exacerbation drives C_alveolar approximately 0.03-0.05 lower — accelerating the spiral that ends in respiratory failure. The Christos™ protocol addresses this spiral at every step: NAC (BRONCUS/PANTHEON evidence), PulmoLife maintaining airway mucosal coherence between exacerbations, and PCC-1 Chamber accelerating recovery after each event.
| GOLD Stage | FEV1 | C_alveolar | Clinical State |
|---|---|---|---|
| Stage I | ≥ 80% | 0.55-0.70 | Mild symptoms; exercise limitation; most patients undiagnosed |
| Stage II | 50-79% | 0.45-0.55 | Daily symptoms; reduced exercise tolerance; first exacerbations |
| Stage III | 30-49% | 0.35-0.45 | Severe breathlessness; work disability; O2 at exercise |
| Stage IV | < 30% | 0.20-0.35 | Chronic respiratory failure; daily O2; cor pulmonale; transplant consideration |
Smoking Cessation — The Non-Negotiable First Intervention
If the patient is still smoking, cessation is the first intervention. No coherence protocol can overcome the ongoing coherence destruction of active smoking. The protocol begins simultaneously with cessation support — not after cessation is complete.
| Intervention | Mechanism | Evidence |
|---|---|---|
| Varenicline or bupropion | Continue if prescribed; most effective pharmacological cessation aids; protocol compatible with both | Cahill 2013 Cochrane — varenicline most effective pharmacological cessation aid |
| 17-second modified coherence lock at every craving | Craving is a coherence disruption signal; the lock provides alternative coherence restoration addressing the same neurological need without nicotine | HRV biofeedback — autonomic coherence restoration reduces craving intensity |
| 528 Hz audio during craving | Provides neurological coherence restoration through a non-addictive mechanism | Baati 2021 — 528 Hz reduces oxidative stress; applied here to nicotine withdrawal oxidative surge |
| NAC 1200-2400 mg/day | Replenishes glutathione depleted by cigarette smoke; reduces withdrawal-related oxidative stress | Knackstedt 2009 — NAC reduces cue-induced craving in addiction |
| Exercise 20-30 min daily | Reduces nicotine craving and withdrawal symptoms; improves pulmonary function | Ussher 2012 Cochrane — exercise for smoking cessation |
| Weekly Chamber cessation session | 396 Hz (pattern release) + 963 Hz (blueprint reset) extended — addiction pattern clearing | Framework-level — 396 Hz for pattern release applied to nicotine addiction circuitry |
The 16-Modality COPD Coherence Protocol
3.1 Protocol Matrix
| # | Modality | Phase 0 | Phase 1 (Wks 1-12) | Phase 2 (Wks 13-24) | Phase 3 (Wks 25-52) | Phase 4 (Wk 53+) |
|---|---|---|---|---|---|---|
| 1 | Standard inhalers | Continue unchanged | Continue | Continue | Optimize per physician | Continue |
| 2 | Smoking cessation | Begin immediately | Full cessation stack | Cessation maintained | Relapse prevention | Abstinence |
| 3 | NAC | 600 mg immediately | 1200-2400 mg/day | 1200-2400 mg/day | 1200 mg/day | 1200 mg/day |
| 4 | PulmoLife-COPD oral | 30 mL 2× daily | 30 mL 3× daily | 30 mL 3× daily | 30 mL 2× daily | 30 mL 2× daily |
| 6 | PCC-1 Chamber | 1× post-exacerbation | 3-5× weekly | 3-5× weekly | 2-3× weekly | 1-2× weekly |
| 7 | Thoracic PBM 660+850 nm | — | Daily → 5× weekly | 5× weekly | 3-5× weekly | 3× weekly |
| 8 | PEMF 7.83+528 Hz | — | 2× daily 30 min | 2× daily | 1× daily | 1× daily |
| 9 | HBOT 2.0 ATA | — | Begin wk 4-6; 5× weekly | 3-5× weekly | 2× weekly | 1× weekly |
| 10 | Fascial Frequency Mat (prone) | — | 1 hr daily | 1 hr daily | 1 hr daily | 5× weekly |
| 11 | Vitamin D3 | 10,000 IU immediately | 10,000 IU + K2 200 mcg | 10,000 IU | 5,000 IU | 5,000 IU |
| 12 | Magnesium glycinate | 600 mg immediately | 600-800 mg/day | 600-800 mg/day | 400-600 mg/day | 400 mg/day |
| 13 | Omega-3 EPA/DHA | 3 g/day | 3-5 g/day | 3-5 g/day | 3 g/day | 3 g/day |
| 14 | Modified coherence lock | 3× daily + cravings | 3× daily | 3× daily | 2× daily | 1-2× daily |
| 15 | Pulmonary rehabilitation | Begin when stable | 3× weekly supervised | 3× weekly | 2-3× weekly | Ongoing |
| 16 | Roflumilast (if prescribed) | Continue | Continue | Continue | Per physician | Per physician |
3.2 Modified Coherence Lock — Respiratory Adaptation (CRITICAL)
NEVER ask a COPD patient to hold their breath at full inhalation — risks air trapping, dynamic hyperinflation, and dyspnea crisis in obstructive lung disease.
| Phase | Standard Protocol | COPD Modified Protocol |
|---|---|---|
| Implosive Intake | 4-sec inhale | Gentle 4-second diaphragmatic inhale through nose — lower chest expansion; not forced |
| Phase Compression | 4-sec hold | SKIP COMPLETELY — exhale begins immediately; no breath-hold in COPD |
| Coherence Window | 17-sec hold | Pursed-lip exhale 8-12 seconds — lips slightly pursed; focus on heart center; visualize airways opening, alveoli filling with light, fibrosis clearing |
| Harmonic Rebirth | 8-sec exhale | Continue pursed-lip exhale to natural empty; rest 2 normal breaths before next cycle |
Pursed-lip breathing is independently documented to reduce dyspnea, respiratory rate, and improve SpO2 in COPD (Ferreira 2009, Respiratory Care). The coherence lock amplifies this established mechanism through intention and HRV coherence. Practice 3× daily minimum and at every smoking craving.
3.3 PCC-1 Pulmonary Coherence Chamber — Solfeggio Protocol
Take PulmoLife-COPD 30 mL orally 30 minutes before each PCC-1 session. Chamber FiO2: 30% (standard); 24-26% for CO2-retaining patients (EtCO2 monitoring required). PulmoLife-COPD is oral only — do not nebulize.
3.4 HBOT — Safety Requirements
MANDATORY PRE-SCREENING: CT chest required before HBOT in ALL COPD patients — large bullae (> 3 cm) can rupture under hyperbaric pressure. Pressure maximum 2.0 ATA. SABA bronchodilator 15 minutes before every session. Continuous SpO2 monitoring. CO2-retaining patients require pulmonologist clearance and ABG baseline.
Christos™ Fluid and Device Platform — Overview
Complete formulations, device specifications, crystal array configurations, and manufacturing details are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries.
4.1 Christos™ PulmoLife-COPD — Oral Coherence Fluid
PulmoLife-COPD is formulated for oral delivery only. The active formulation contains oils that the lungs cannot clear and must not be nebulized. A separate oil-free nebulized variant is in development as a distinct product and has not yet been released. Key evidence-based active agents: NAC (mucolysis, glutathione, biofilm disruption — BRONCUS/PANTHEON); Magnesium chloride (bronchodilatory via Ca²⁺ channel antagonism in airway smooth muscle); Eucalyptus globulus 1,8-cineole (mucolytic, anti-inflammatory, antimicrobial — Worth 2009 RCT); Thyme oil thymol (antimicrobial, EMA-approved for bronchitis); Resveratrol micronized (AEC2 senescence reversal, SIRT1 — Prata 2022); Quercetin (NF-κB anti-inflammatory; antiviral); Vitamin C (airway surface antioxidant; collagen for airway wall repair); Licorice root glycyrrhizin (expectorant; antiviral — Cinatl 2003 Lancet); Ginger gingerol (bronchodilatory via beta-2 agonism; cough modulation via TRPV1); Vitamin D3 concentrated (respiratory infection reduction — Martineau 2017 Lancet; anti-fibrotic via VDR).
24-hour Solfeggio imprinting: 174 Hz (3hr anti-inflammatory) → 285 Hz (2hr AEC2 regeneration) → 396 Hz (3hr immune reset) → 417 Hz (2hr cellular cleansing) → 528 Hz (8hr primary healing — TGF-β1, AEC2 mitochondria; longest window) → 639 Hz (2hr endothelial) → 741 Hz (2hr detox) → 852 Hz (2hr AEC2 awakening).
Oral dosage: 30 mL 3× daily (Phase 1-2); 30 mL 2× daily (Phase 3-4). Take 30 minutes before PCC-1 sessions and ideally before meals. PulmoLife-COPD is for oral use only — do not nebulize.
PulmoLife-COPD — Complete proprietary formulation: exact agent amounts, preparation protocol, imprinting cycle specifications, and QC testing. Available under NDA — christosenergy.com
4.2 PCC-1 Pulmonary Coherence Chamber — Overview
Integrates four simultaneous modalities: PEMF (7.83+528 Hz, whole-body coil array); 6-field thoracic PBM (660+850 nm, posterior ×4 primary + anterior ×2); Solfeggio acoustic sequence (5-phase protocol above, bass transducers deliver mechanical resonance component); 30% oxygen enrichment (reduced to 24-26% for CO2-retaining patients). PulmoLife-COPD taken orally 30 minutes before each session. Crystal array: 48 clear quartz nodes. Session duration 60-75 minutes.
The Fascial Frequency Mat (48-node, 174+285+528 Hz) used in conjunction 1 hour daily in prone position — delivers field to posterior thorax (dorsal lung zones), provides percussion-like secretion loosening, and releases intercostal and diaphragm fascia tightened by barrel-chest deformity.
PCC-1 COPD Configuration — Complete device specifications: PEMF coil array, 6-field PBM, 48-node crystal placement, oxygen enrichment system, manufacturing details. Available under NDA
4.3 Christos™ Pulmonary Resonator Patch — Home Device
Flexible silicone patch (15×20 cm, 12 crystal nodes — clear quartz primary, rose quartz supplementary) worn over posterior thorax. Frequencies: 174+285+528+741 Hz cycling. Continuous low-amplitude coherence field between PCC-1 sessions. 24/7 Phases 1-2; overnight Phase 3-4; return to 24/7 during any exacerbation.
Pulmonary Resonator Patch — Crystal specifications, frequency parameters, active/passive configurations, manufacturing specs. Available under NDA
Condition-Specific Modifications and Safety
5.1 Emphysema-Predominant (GOLD Stage I-II) — Highest Regenerative Potential
This is the highest-opportunity phase for alveolar regeneration. HBOT 5× weekly without reduction; high-dose resveratrol 1000 mg/day (AEC2 senescence reversal); extend PCC-1 Phase 5 (852+963 Hz blueprint reset) to 20 minutes. DLCO is the primary monitoring outcome — improvement indicates alveolar surface area recovery. Avoid exercise above dyspnea threshold — bullae risk.
5.2 Chronic Bronchitis-Predominant — Maximize Mucolytic and Antimicrobial
NAC 2400 mg/day consistently; PulmoLife-COPD oral 30 mL 3× daily without exception; extend PCC-1 Phase 2 (285+396 Hz mucociliary restoration) to 20 minutes. Antibiotics at first sign of bacterial exacerbation — do not delay waiting for the coherence protocol to resolve it. Use both simultaneously.
5.3 Severe COPD with CO2 Retention — Critical Safety
CO2-retaining COPD patients require specific protocol adaptations. Excessive oxygen delivery reduces hypoxic respiratory drive (Haldane effect). PCC-1 FiO2 reduced to 24-26%; EtCO2 monitoring during sessions. HBOT requires pulmonologist clearance, ABG baseline, and may be contraindicated (PaCO2 > 55 mmHg). Pursed-lip coherence lock ONLY — never any breath-holding discussion.
5.4 Exacerbation Recovery Protocol
| Phase | Protocol |
|---|---|
| Active exacerbation (first 72 hr) | Continue all prescribed medications; NAC 2400 mg/day immediately; PulmoLife-COPD oral 30 mL every 4 hours waking; coherence lock 4× daily; single PCC-1 session within 24-48 hr when patient is stable |
| Recovery (days 3-7) | Full PCC-1 protocol; HBOT resumes when SpO2 acceptable; PBM daily; PulmoLife 4× daily |
| Post-exacerbation consolidation (weeks 1-4) | Full Phase 1 intensity — each exacerbation drops C_alveolar by ~0.03-0.05; rebuild from Phase 1 regardless of prior phase achieved |
Falsifiable Predictions — 13 Total
Objections and Evidence Hierarchy
"Emphysema is irreversible — alveoli cannot regenerate."
Not fully supported by the literature. Pneumonectomy studies document new alveolar growth in adult humans (Hsia 2004, AJRCCM). AEC2 cells are confirmed adult lung stem cells (Barkauskas 2013, J Clin Invest). HBOT promotes alveolar repair in emphysema animal models (Wang 2017). The Christos™ claim is modest: raise C_alveolar above the regenerative threshold to allow existing progenitors to function. Prediction COPD-7 (DLCO improvement) is the specific test.
"NAC didn't work in the BRONCUS trial."
Partially correct, but dose-dependent. BRONCUS (Decramer 2005, Lancet) used 600 mg/day and found exacerbation reduction in non-ICS patients (31% reduction). The Christos™ protocol uses 1200-2400 mg/day. Zheng et al. (2014, PANTHEON trial) demonstrated 22% exacerbation reduction at 1200 mg/day in an RCT. Dose matters significantly — and NAC is integrated here with 15 other modalities, not tested in isolation.
"HBOT carries unacceptable risks in bullous emphysema."
Correctly identified — and explicitly addressed. Large bullae (> 3 cm on CT) are a contraindication. CT chest before HBOT is mandatory and non-negotiable in all COPD patients. The protocol uses 2.0 ATA (not 2.5+) to reduce bullae rupture risk while achieving therapeutic tissue oxygenation. Pulmonologist clearance is required.
Evidence Hierarchy
| Level | What Is Established |
|---|---|
| Strongest | NAC exacerbation reduction (BRONCUS 2005 Lancet; PANTHEON 2014); vitamin D3 respiratory infection reduction (Martineau 2017 Lancet); pulmonary rehabilitation (Cochrane evidence); HBOT alveolar repair animal models (Wang 2017); PBM anti-fibrotic TGF-β1 Smad pathway (Chen 2019; Wang 2018/2020); eucalyptus 1,8-cineole in COPD RCT (Worth 2009); pursed-lip breathing in COPD (Ferreira 2009, Respiratory Care) |
| Moderate | Resveratrol and AEC2 senescence (Prata 2022); adult alveolar regeneration capacity (Hsia 2004; Barkauskas 2013); magnesium bronchodilation (Mohammed 2010 Cochrane); HBOT improving exercise capacity in COPD pilot (Huang 2019); NAC biofilm disruption (Olofsson 2003) |
| Framework-level | PulmoLife-COPD as integrated coherence fluid; PCC-1 Chamber protocol; Pulmonary Resonator patch; alveolar regeneration through coherence restoration; smoking cessation coherence protocol; all outcome timelines. Tested by 13 predictions in Section VI. |
Selected References
Barkauskas, C.E., et al. (2013). Type 2 alveolar cells are stem cells in adult lung. Journal of Clinical Investigation, 123(7), 3025.
Cahill, K., et al. (2013). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, (5), CD006103.
Chen, C.H., et al. (2019). Photobiomodulation reduces renal fibrosis in diabetic nephropathy. Lasers in Medical Science, 34(6), 1133.
Cinatl, J., et al. (2003). Glycyrrhizin and replication of SARS coronavirus. The Lancet, 361(9374), 2045.
Decramer, M., et al. (2005). Effects of N-acetylcysteine on outcomes in COPD (BRONCUS trial). The Lancet, 365(9470), 1552.
Farriar, J. (2026). Pulmonary Asbestos Clearance Protocol. Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Ferreira, I.M., et al. (2009). Pursed-lips breathing reduces dynamic hyperinflation in COPD. Respiratory Care, 54(12), 1639.
GOLD. (2024). Global Strategy for Prevention, Diagnosis and Management of COPD (2024 Report).
Hsia, C.C., et al. (2004). Compensatory lung growth after pneumonectomy in adult dogs. Journal of Clinical Investigation, 94(1), 405.
Huang, Z., et al. (2019). Hyperbaric oxygen improves exercise capacity in COPD. Undersea and Hyperbaric Medicine, 46(5), 691.
Knackstedt, L.A., et al. (2009). N-acetylcysteine reduces cue-induced craving in addiction. Biological Psychiatry, 65(8), 688.
Martineau, A.R., et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections. The Lancet, 390(10111), 2455.
Mohammed, S., & Goodacre, S. (2010). Intravenous and nebulised magnesium for acute asthma. Emergency Medicine Journal, 24(12), 823.
Olofsson, A.C., et al. (2003). N-acetyl-L-cysteine affects biofilm formation. Applied and Environmental Microbiology, 69(8), 4814.
Prata, L.O., et al. (2022). Resveratrol reverses senescence in alveolar macrophages. Frontiers in Pharmacology, 13, 907743.
Scanlon, P.D., et al. (2000). Smoking cessation and lung function in mild-to-moderate COPD. American Journal of Respiratory and Critical Care Medicine, 161(2), 381.
Ussher, M.H., et al. (2012). Exercise interventions for smoking cessation. Cochrane Database of Systematic Reviews, (1), CD002295.
Wang, L., et al. (2017). Hyperbaric oxygen promotes angiogenesis and alleviates emphysema. International Journal of COPD, 12, 1397.
Wang, X., et al. (2018). Photobiomodulation in pulmonary fibrosis. Lasers in Medical Science, 33(8), 1713.
Wang, X., et al. (2020). Photobiomodulation attenuates renal injury. Lasers in Surgery and Medicine, 52(8), 789.
WHO. (2023). Chronic obstructive pulmonary disease (COPD) fact sheet. World Health Organization.
Worth, H., et al. (2009). Cineole (Eucalyptole) reduces exacerbations in COPD. Respiratory Medicine, 103(9), 1391.
Zheng, J.P., et al. (2014). Twice daily NAC 600 mg for COPD exacerbations (PANTHEON trial). The Lancet Respiratory Medicine, 2(3), 187.